Results 61 to 70 of about 13,385 (164)

Long‐Term Use of Rezafungin: A Case Report and Insights Into Real‐World Access

open access: yes
Transplant Infectious Disease, EarlyView.
Jian Mei Li   +2 more
wiley   +1 more source

Antifungal Susceptibility Profile and Biocide Tolerance in Clinically Relevant Yeasts: Implications for Therapy and Hospital Infection Control

open access: yesMycoses, Volume 69, Issue 9, September 2026.
ABSTRACT Background Opportunistic yeasts account for a substantial proportion of invasive fungal infections and are important agents of healthcare‐associated infections, especially in intensive care units (ICUs). Objectives To describe the clinical and epidemiological characteristics of hospitalized patients with positive cultures for medically ...
Yasmim Passos Lima   +8 more
wiley   +1 more source

Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris

open access: yes, 2018
Candida auris has simultaneously emerged on five continents as a fungal pathogen causing nosocomial outbreaks. The challenges in the treatment of C.
David S. Perlin   +13 more
core   +1 more source

Genotypes, Fluconazole Tolerance and Virulence Phenotypes of Candida albicans Bloodstream Isolates: A Multilocus Sequence Typing‐Based Analysis

open access: yesMycoses, Volume 69, Issue 9, September 2026.
ABSTRACT Background Fluconazole tolerance is an emerging phenotype in Candida albicans bloodstream infections, but its relationship to multilocus sequence typing (MLST) lineages and virulence traits is unclear. Objectives To investigate the relationships among MLST genotypes, fluconazole tolerance, and virulence phenotypes in C.
Shang‐Yi Lin   +5 more
wiley   +1 more source

Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. [PDF]

open access: yes, 2013
International audienceOBJECTIVES: Candida albicans is the most prevalent fungal pathogen of humans, causing a wide range of infections from harmless superficial to severe systemic infections. Improvement of the antifungal arsenal is needed since existing
Doyen, Antonia   +10 more
core   +1 more source

A Multifactorial Azole Response in Clinically Relevant Fusarium Species Complexes

open access: yesMycoses, Volume 69, Issue 9, September 2026.
ABSTRACT Background Fusarium spp. are clinically relevant filamentous fungi with intrinsically low susceptibility to multiple antifungal agents, particularly azoles, and are included in the World Health Organization fungal priority pathogens list.
Patrícia Helena Grizante Barião   +5 more
wiley   +1 more source

Multidimensional assessment of in-host fitness costs of echinocandin resistance in the opportunistic fungal pathogen Candida glabrata reveals the niche-specific requirement for FKS1 and FKS2 during infection and gut colonization

open access: yesAntimicrobial Agents and Chemotherapy
Host stresses are often considered a major barrier against the emergence of echinocandin resistance (ECR) in prominent infecting organisms like Candida albicans due to fitness defects. Yet, ECR strains of C.
Amir Arastehfar   +9 more
doaj   +1 more source

Clinically Important Emerging and Uncommon Fungal Pathogens in Asia: Epidemiology, Antifungal Resistance and Challenges in Diagnosis and Management

open access: yesMycoses, Volume 69, Issue 9, September 2026.
ABSTRACT Fungal infections in Asia are influenced by warm, humid climates, high population density and expanding healthcare systems, which together facilitate the emergence, transmission and detection of both common and rare pathogens. While Candida and Aspergillus species remain the leading causes of invasive fungal disease, increasing attention has ...
Narut Chancharussin   +3 more
wiley   +1 more source

Antifungal Echinocandin

open access: yes, 2019
Infeksi fungal invasif (IFI) masih menjadi penyebab utama morbiditas dan mortalitas pasien immunocompromised. Pilihan antifungal yang tersedia untuk IFI terbatas pada polyene, triazole, dan echinocandin.
Lukito, J. I. (Johan)
core  

Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Acute myeloid leukemia (AML) represents 15% to 20% of all pediatric acute leukemias and is responsible for nearly 30% of deaths in this population. While high‐income countries report overall survival (OS) rates near 75%, survival in Brazil remains significantly lower, ranging between 30% and 40%.
Thais Alcantara Bonilha   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy